Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

Inclusion criteria:

• Moderate to severe AtD (confirmed by a dermatologist) according to the Hannifin andRajka criteria or Eichenfield revised criteria.

• Onset of AtD symptoms occurring at least 6 months prior to Screening, with stabledisease for at least 1 month prior to Screening.

• Eczema Activity Severity Index greater than or equal to (>=)16; Investigator GlobalAssessment score >=3.

• Group 1- Biologic Naïve: Topical First Line Treatment: Documented recent history (within 6 months before Screening) of: a) either an inadequate response (IR) toout-patient treatment with at least one topical treatment (intermittent topicalcorticosteroid, topical calcineurin inhibitor), topical inhibitors orPhosphodiesterase 4 inhibitor (Crisaborole); b) or that topical treatments wereotherwise not recommended.

• Group 2- Dupilumab-Inadequate Responder: Documented history of an IR to dupilumab:a) either following at least 16 weeks of treatment according to the Investigator'sjudgement; b) or intolerant to dupilumab owing to adverse events.

Exclusion Criteria:

• Other than AtD, the presence of a significant skin morbidity that will influence theInvestigator's ability to assess the severity of the disease (e.g. psoriasis,confirmed or suspected cutaneous T-cell lymphoma, autoimmune bullous disease, fixeddrug reaction and Stevens Johnson Syndrome).

• Participants with any uncontrolled medical conditions, other than AtD, that in theopinion of the investigator puts the participant at unacceptable risk or will likelyinterfere with study assessments or data integrity. Other medical conditions shouldbe stable at the time of screening and be expected to remain stable for the durationof the study.

• Treatment with biologic agents (investigational and marketed monoclonal antibodies)within 12 weeks or 5 pharmacokinetic half-lives (whichever is longer) prior dosingon Day 1.

• Treatment with Janus Activated Kinase inhibitors (e.g. baricitinib, upadacitinib)within 4 weeks or 5 half-lives (whichever is longer) prior to dosing on Day 1.

• Mycophenolate mofetil, azathioprine, methotrexate, or calcineurin inhibitors within 4 weeks of Screening.